US Pharma MarketingThe post FDA approves Guardant Health’s next-generation liquid biopsy panel appeared first on Medical Device Network.
FDA approves Guardant Health’s next-generation liquid biopsy panel
According to Guardant, Guardant360 Liquid assesses a ‘100x wider’ genomic footprint to guide cancer treatment decisioning than its predecessor. According to Guardant, Guardant360 Liquid assesses a ‘100x wider’ genomic footprint to guide cancer treatment decisioning than its predecessor. Guardant expects 2026 revenue growth between $1.25bn and $1.28bn, indicative of a 27%-30% rise YoY. Credit: viewimage / Shutterstock.com Guardant Health has secured US Food and Drug Administration (FDA) approval for its next generation liquid biopsy panel for informing cancer treatment decisions, combining genomic and epigenomic profiling to reveal further insight for cancer patients via a blood draw. Guardant360 Liquid’s approval covers…
According to Guardant, Guardant360 Liquid assesses a ‘100x wider’ genomic footprint to guide cancer treatment decisioning than its predecessor.
Source: Medical Device Network